Kara Cossis, PA
Physician Assistant · Baltimore, MDNPI 1831281872
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Johnson & Johnson at 30.9% of the total. 2025 is the largest year on record at $49,823, 4.4 times the $11,327 reported in 2021. Among physician assistant clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 653 payments — averaging $271.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$55K
- Astellas Pharma US Inc$31K
- Bayer$28K
- AstraZeneca$19K
- Myriad Genetic Laboratories, Inc.$14K
- Tolmar Pharmaceuticals, Inc.$10K
- plus $20K from 32 others
What the payments were for
- Consulting fees$24,24514%
- Speaking & faculty fees$99,41856%
- Travel & lodging$36,61521%
- Food & beverage$16,2159%
- Education$5540%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 160 | $54,798 |
| Astellas Pharma US Inc | 64 | $30,559 |
| Bayer | 76 | $28,418 |
| AstraZeneca | 38 | $19,282 |
| Myriad Genetic Laboratories, Inc. | 47 | $13,747 |
| Tolmar Pharmaceuticals, Inc. | 36 | $9,991 |
| Amgen | 42 | $8,964 |
| Pfizer | 48 | $3,392 |
| Accord Healthcare, Inc. | 17 | $3,321 |
| Novartis | 7 | $902 |
| Sumitomo Pharma America, Inc. | 23 | $422 |
| AbbVie | 15 | $352 |
| Dendreon Pharmaceuticals LLC | 9 | $338 |
| Teleflex LLC | 3 | $258 |
| Progenics Pharmaceuticals, Inc. | 5 | $257 |
| Radius Health, Inc. | 5 | $209 |
| Urovant Sciences Inc | 4 | $180 |
| Tempus AI, Inc | 2 | $176 |
| Boston Scientific | 3 | $159 |
| Endo Pharmaceuticals Inc. | 3 | $147 |
| Merck | 8 | $145 |
| Myovant Sciences Inc. | 7 | $137 |
| Axonics, Inc. | 2 | $106 |
| Ferring Pharmaceuticals Inc. | 3 | $100 |
| Urogen Pharma, Inc. | 2 | $98 |
| Globus Medical | 1 | $91 |
| Blue Earth Diagnostics | 4 | $88 |
| Janssen Scientific Affairs, LLC | 3 | $71 |
| Bioprotect Medical, Inc. | 3 | $69 |
| Foundation Medicine, Inc. | 3 | $62 |
| Clovis Oncology, Inc. | 2 | $40 |
| Olympus America Inc. | 2 | $39 |
| Sanofi | 1 | $35 |
| Valencia Technologies Corporation | 1 | $32 |
| 180 Medical, Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Hollister Incorporated | 1 | $18 |
| Medtronic | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$177,064 in reported general payments places this provider in the 95th percentile of 2,567 physician assistant providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 21 | $320,692 |
| Abiraterone Acetate | 40 | $213,274 |
| MyrbetriqMirabegron | 11 | $7,988 |
| Tamsulosin Hcl | 16 | $241 |
| Prednisone | 42 | $226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $30,559 | $328,68032 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $71 | $213,27440 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,567 physician assistant providers in Maryland.
Other physician assistant in Baltimore
- Melissa BearekmanBaltimore$81K
- Praveena GadamBaltimore$24K
- James ShafferBaltimore$12K
- Joyce FreidlyBaltimore$10K
- Maria RosenbergBaltimore$10K
- Thomas PetryBaltimore$10K
- Melanie GreenwayBaltimore$10K
- Margaret JoyceTowson$220K
- Garland JamesSilver Spring$86K
- Brittany YerkesSalisbury$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.